wellrank.ai
Paperwork AI logo

Paperwork AI

First cited by AI Jun 12, 2026
paperwork.ai

Surfaced organically in AI answers about compounded glp-1s. Not yet profiled.

Paperwork AI is losing the AEO war.

Not cited in a single tracked AI answer since Jun 12, 2026, down from a peak of 2% visibility in compounded glp-1s on Jun 12, 2026. This page and its history stay public, and recovery shows here the day it happens.

AI Visibility

Visibility trend

Compounded GLP-1s, daily share of AI answers mentioning Paperwork AI, through Jun 13, 2026.

0.0%

Last cited Jun 12, 2026 · peak 2% on Jun 12

By engine

Where Paperwork AI is strong, and where it is invisible.

  • No engine data yet.

Mention sentiment

Tone of AI mentions across all tracked answers.

  • 1 positive mentions
  • 0 neutral
  • 0 mixed or cautious

Recent AI answers mentioning Paperwork AI

ClaudeJun 12, 2026, 10:28 UTC
My insurance denied Wegovy. Are compounded GLP-1s my best option?

This is a common situation right now. Here are your realistic options to consider: Compounded GLP-1s (Semaglutide) Possible, but with important caveats: Hims/Hers, LifeMD, Ro offer compounded semaglutide, typically $200-300/month Since brand-name Wegovy is no longer on the FDA shortage list, compounding pharmacies may soon lose legal authority to make it - this is an evolving situation Quality varies; look for pharmacies using 503B outsourcing facilities for better oversight Potentially Better Alternatives First Appeal your denial: Paperwork AI or your doctor can help draft appeals Many denials get overturned with prior authorization documentation Manufacturer savings programs: Novo Nordisk's savings card can reduce Wegovy to ~$650/month or less if you have commercial insurance Consider Zepbound (tirzepatide): Often easier to get approved than Wegovy May actually be more effective Eli Lilly's savings program can bring it to ~$550/month Retail alternatives: Ozempic (same drug, different indication) sometimes easier to approve My Honest Recommendation Talk to your doctor about switching the prescription to Zepbound before going the compounding route, given the regulatory uncertainty. Would you like more detail on any of these options?

Mentioned in position 4 of 6

Read full answer with sources →

Public AI visibility history

Daily rank of Paperwork AI on our buyer intent questions, per category. A dash means the engines did not cite Paperwork AI at all that day. This record is permanent.

CategoryJun 11Jun 12Jun 13
Compounded GLP-1s#92

Competitive Landscape

Paperwork AI vs the brands AI recommends alongside it

The real competitive set in Compounded GLP-1s: brands the engines name in the same answers, ranked on the latest day.

BrandRankAI visibility
Paperwork AI logo
Paperwork AIThis brand
0.0%
Eli Lilly logo
Eli Lilly

1 shared answers

#7
16.7%
Hims & Hers logo
Hims & Hers

1 shared answers

#1
41.7%
LifeMD logo
LifeMD

1 shared answers

#11
16.7%
Novo Nordisk logo
Novo Nordisk

1 shared answers

#6
16.7%

Email me when overtakes Paperwork AI

One email the day the ranks flip. Nothing else.

Sources cited around Paperwork AI

The sites engines cite in answers mentioning this brand. Win these, win the answer.

    Track Paperwork AI weekly

    One email a week: rank moves, new competitors, and the answers that changed. No noise.

    Work at Paperwork AI? Get your AI Visibility Audit.

    See every buyer intent question your customers ask AI, which ones you are losing, who wins them instead, and the exact sources driving those answers. You will finally understand your buyer intent and what Propel would do to win it.